A5081255723- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Systemic Lupus Erythematosus Research
- Liver Diseases and Immunity
- Cytomegalovirus and herpesvirus research
- Hepatitis Viruses Studies and Epidemiology
- Hepatocellular Carcinoma Treatment and Prognosis
- Gallbladder and Bile Duct Disorders
- Biochemical and Molecular Research
- Immune Cell Function and Interaction
- HIV/AIDS drug development and treatment
- Animal Virus Infections Studies
- HIV Research and Treatment
- Diabetes and associated disorders
- Radiomics and Machine Learning in Medical Imaging
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Diet, Metabolism, and Disease
- SARS-CoV-2 and COVID-19 Research
- Pediatric Hepatobiliary Diseases and Treatments
- Medical Imaging Techniques and Applications
- Erythrocyte Function and Pathophysiology
- Organ Transplantation Techniques and Outcomes
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2016-2025
Ospedale Maggiore
2013-2025
University of Milan
2013-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2023
IRCCS Policlinico San Donato
2022
Université Claude Bernard Lyon 1
2022
National University of Health Sciences
2022
Center for Digestive and Liver Diseases
2021
University of Naples Federico II
2013
University of Campania "Luigi Vanvitelli"
2013
Chronic hepatitis D is the most debilitating form of viral frequently progressing to cirrhosis and subsequent decompensation. However, HDV entry inhibitor bulevirtide only approved for antiviral treatment patients with compensated disease. We aimed analysis real-world data on off-label use in setting decompensated liver cirrhosis.
Summary Background Noninvasive tests (NITs) have been proposed as an alternative to liver biopsy for diagnosing cirrhosis. The evidence of NIT performance in patients with chronic hepatitis D (CHD) is limited. Aims To evaluate the diagnostic stiffness measurement (LSM) and other NITs CHD patients. Methods We evaluated LSM by transient elastography detection cirrhosis a retrospective, multicentre cohort 144 paired (±6 months) biopsies. Results Cirrhosis was diagnosed histologically 22...
•Overall high effectiveness of VOX/VEL/SOF was demonstrated in an integrative analysis large real-world studies.•Significantly lower SVR rates were observed patients with GT3, advanced liver disease, HCC onset and VEL/SOF pretreatment.•RASs as well rare genotypes chimera did not impact following re-treatment.•Cirrhosis, GT3 identified independent negative predictors treatment response to VOX/VEL/SOF. Background & AimsVoxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is highly effective for...
Hepatitis C virus (HCV) infection is associated with insulin resistance (IR), which a condition known to influence the progression of liver fibrosis and response pegylated interferon (PEG-IFN)/ribavirin (RBV) therapy. We aimed assess whether sustained virological (SVR) after antiviral therapy prevents development IR in long term. Members Milan Safety Tolerability study cohort, who received PEG-IFNα2a/RBV or PEG-IFNα2b/RBV, underwent homeostasis model assessment (HOMA) at baseline 24 months...
Background and Aims Genetic factors steatosis predispose to hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus; however, their impact cirrhosis cured by direct‐acting antivirals (DAAs) is still undefined. We assessed the association between a genetic risk score (GRS) of hepatic fat accumulation, combining variants PNPLA3 (patatin‐like phospholipase domain containing 3), MBOAT7 (membrane bound O‐acyltransferase 7), TM6SF2 (transmembrane 6 superfamily member 2), GCKR...
Background and Aims Liver fibrosis holds a relevant prognostic meaning in primary biliary cholangitis (PBC). Noninvasive evaluation using vibration‐controlled transient elastography (VCTE) is routinely performed. However, there limited evidence on its accuracy at diagnosis PBC. We aimed to estimate the diagnostic of VCTE assessing advanced (AF) disease presentation Approach Results collected data from 167 consecutive treatment‐naïve PBC patients who underwent liver biopsy (LB) six Italian...
The utility of Baveno-VII criteria clinically significant portal hypertension (CSPH) to predict decompensation in compensated advanced chronic liver disease (cACLD) patient needs validation. We aim validate the performance CSPH risk an international real-world cohort cACLD patients.
Objective A convenient, reproducible biomarker of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) transcriptional activity is lacking. We measured circulating HBV RNA (cirB-RNA) in untreated and nucleos(t)ide analogues (NUC) treated chronic (CHB) patients to define its correlation with intrahepatic viral markers core-related antigen (HBcrAg). Design Paired liver biopsy serum samples were collected from 122 30 NUC-treated CHB patients. cirB-RNA, DNA, surface (HBsAg), HBcrAg...
Chronic liver inflammation leads to fibrosis and cirrhosis is associated with an accumulation of intrahepatic TNFα-secreting CD206+ macrophages, which may participate in maintaining chronic disease a GM-CSF-dependent manner. We aimed elucidate the exact role GM-CSF development progression disease.Liver immunohistochemistry serum quantification were performed patients viral non-viral-related compare monocyte/macrophages, GM-CSF. This was followed by functional validations vitro vivo humanised...
Background & Aims: Virus-specific T cells are crucial for controlling viral replication and disease progression in chronic hepatitis B (CHB). Nevertheless, due to the complexity of their analysis, CHB management relies exclusively on virological biochemical markers. We aimed develop a point-of-care immunological test, HBV-cytokine release assay (HBV-CRA), designed measure multiple cytokines whole blood after HBV-peptide pool stimulation. Methods: first assessed assay′s sensitivity by...